Tirzepatide - Frequently Asked Questions

  • Tirzepatide is the active ingredient found in the brand-name medications Mounjaro™ and Zepbound™. Tirzepatide combines a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor, both of which are found in areas of the brain that regulate appetite. 

  • While every individual responds differently to medications, a medical study of 783 participants demonstrated that in a 88-week period, participants lost an average body weight of ~26.6%. 

    • Adults with a BMI of 30 or more (obesity category). 

    • Adults with a BMI of 27-29 (overweight category), who also have at least one weight-related comorbid condition such as hypertension, diabetes type 2, or hyperlipidedemia. 

  • Tirzepatide can be administered weekly, at any time of day but on the same day each week, with or without meals. 

  • Tirzepatide should be injected subcutaneously into upper arms, abdomen or thighs. 

  • The maintenance dose of Tirzepatide is 10-15 mg once weekly. 

  • If there is a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MENS2) or in case of hypersensitivity to Tirzepatide. 

  • The most common side effects of Tirzepatide include nausea, diarrhea/constipation, feeling bloated, heartburn, belching, dizziness, vomiting, and upset stomach. With 1:1 Board Certified Primary Care we can help combat these side effects. 

  • Tirzepatide is dispensed by our contracted pharmacy.  

  • To schedule a Telehealth virtual visit, you can click on the Book An Appointment tab.

  • Unfortunately, we are not accepting insurance for the weight loss program at this time. 

  • We do not offer refunds for orders placed, goods received, and/or services rendered. Following FDA regulations, all prescription medications once dispensed by the pharmacy cannot be returned.